Skip to main content

After Weighting, 3.6 Million Likely to Be Newly Eligible for Semaglutide

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 27, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Aug. 26, 2024 -- Increases in eligibility for semaglutide are discussed in a research letter published online Aug. 27 in the Annals of Internal Medicine.

After the Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity trial showed that semaglutide reduced cardiovascular events in certain patients without diabetes, Medicare announced it would allow Part D to cover semaglutide. Alexander Chaitoff, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues identified Medicare beneficiaries most likely to be newly eligible for semaglutide and estimated the maximum costs to Part D.

The researchers found that overall, 5,111 Medicare-eligible adults (about 61 percent) with complete data had a body mass index (BMI) of 27 kg/m2 or more. After weighting, 3.6 million people (14.2 percent) were highly likely to be newly eligible for semaglutide; this number could increase to 15.2 million people (60.9 percent) using more liberal definitions of established cardiovascular disease (CVD). Maximum Medicare spending could be an additional $34 to $145 billion annually if all newly eligible beneficiaries received semaglutide. The demographics of newly eligible patients will depend on the definition of established CVD, but younger, generally healthier, female Medicare beneficiaries are likely to remain ineligible.

"Although approximately one in seven Medicare beneficiaries with elevated BMI is likely to be newly eligible for semaglutide, the majority will remain ineligible if a narrow definition of established CVD is used by Part D plans," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2024

Read this next

Standard-Criteria Kidney Transplant Offers Clear Survival Benefit Over Continued Dialysis

TUESDAY, June 10, 2025 -- Transplantation with standard-criteria kidney offers a clear survival benefit, but this decreases with age and for those with a history of cardiovascular...

Increasing Proportion of U.S. Adults Unaware They Have Hypertension

MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...

Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM

MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.